# 2025年12月9日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 小鼠遗传定位研究的荟萃分析揭示了当前药物开发格局之外的候选癫痫修饰基因

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41358547)
**期刊：** Epilepsia
**PMID：** 41358547
**DOI：** 10.1111/epi.70035

### 第一部分 原文与翻译

**英文原标题：** Meta-analysis of genetic mapping studies in mice reveals candidate epilepsy modifier genes that are outside the current drug development landscape.

> **英文摘要：**
> OBJECTIVE: Despite decades of development in anti-seizure medications, ~30% of individuals remain refractory to all treatments, and none of the existing therapies are disease modifying. Identifying targets outside the current preclinical paradigm is critically important. This study aimed to characterize the landscape of current epilepsy treatments at the level of gene interaction networks and identify novel genetic modifiers of epilepsy as potential novel therapeutic targets.
> 
> METHODS: We performed a functional network analysis to score genes based on their interactions with known epilepsy genes, and we integrated these functional scores with population genetics data and drug tractability information. In parallel, we performed a meta-analysis of genome-wide association studies of epilepsy-related phenotypes in genetically diverse mice using a large compendium of historical phenotyping data. Genes within mapped loci were prioritized based on functional rankings, and genomic evolutionary rate profiling (GERP) was used to identify highly single-nucleotide polymorphisms at evolutionarily constrained positions.
> 
> RESULTS: Functional network analyses of known epilepsy genes revealed a strong involvement of neurodevelopmental processes in epilepsy pathogenesis, which are not targeted by existing or emerging treatments. Meta-analysis of seizure traits in mice identified 118 non-overlapping loci harboring potential seizure phenotype modifiers. Using functional rankings, we prioritized 168 candidate genes within these loci and used GERP scores to filter down to 75 SNPs as candidate variants within these genes. Among them, five genes-Ephb2, En2, Cadps2, Igsf21, and Cep170-contain regulatory variants in evolutionarily constrained sites. Four of these genes are validated as modifiers of neurological traits, including epilepsy susceptibility.
> 
> SIGNIFICANCE: This study prioritized epilepsy modifier genes that are strongly predicted to influence neurodevelopmental processes, which are underrepresented among current therapeutic targets. Furthermore, the identified genes represent novel candidate modifiers with potential clinical relevance. Our systems-level analysis offers a novel view into the potential target landscape, pointing toward promising new directions for disease-modifying treatments.

> **中文摘要：**
> 目的：尽管抗癫痫药物的研发已持续数十年，约有30%的患者对所有治疗仍然顽固不敏感，且目前的疗法均不具疾病修饰作用。识别当前临床前范式之外的潜在靶点至关重要。本研究旨在从基因相互作用网络层面对现有癫痫治疗格局进行特征化，并识别癫痫的新型遗传修饰因子，作为潜在治疗靶点。
> 
> 方法：我们进行了功能网络分析，根据基因与已知癫痫基因之间的相互作用对其进行评分，并将这些功能评分与群体遗传学数据和药物可成药性信息整合。同时，我们利用大量历史表型数据，对遗传多样性小鼠中与癫痫相关表型的全基因组关联研究进行了荟萃分析。位于定位区域内的基因根据功能排序优先级进行筛选，并通过基因组进化速率分析（GERP）识别存在于进化受限位点的高置信单核苷酸多态性。
> 
> 结果：对已知癫痫基因的功能网络分析显示，神经发育过程在癫痫发病机制中发挥重要作用，而该过程并未被现有或新兴疗法所靶向。小鼠癫痫表型的荟萃分析鉴定出118个不重叠的位点，包含潜在的癫痫表型修饰因子。通过功能评分对这些位点内的168个候选基因进行优先排序，并利用GERP评分筛选出75个位于这些基因内的候选变异SNP。在其中，Ephb2、En2、Cadps2、Igsf21和Cep170五个基因在进化受限位点上含有调控性变异。其中四个基因已被验证可调节包括癫痫易感性在内的神经系统表型。
> 
> 意义：本研究优先筛选出一批强烈预测能影响神经发育过程的癫痫修饰基因，而这类基因在现有治疗靶点中仍明显不足。此外，所鉴定出的基因代表了具有潜在临床意义的新型候选修饰因子。本研究的系统层面分析为潜在靶点格局提供了新视角，并指向可能实现疾病修饰治疗的有前景方向。

### 第二部分 AI 大师评价

该研究系统整合了基因功能网络分析、小鼠全基因组关联荟萃研究及进化约束评分，全面描绘了癫痫遗传修饰基因的潜在靶点网络。结果揭示神经发育相关基因在癫痫发病机制中的关键作用，而这些路径目前仍未被药物研发充分涉及。研究通过跨物种、多层次数据融合，提出了多种具有临床潜力的新型候选基因，体现了较强的创新性。但其主要局限在于验证深度不足及从模型动物到人类临床转化的挑战。

---

## 2. 更新版国际抗癫痫联盟（ILAE）发作分类在二级转诊中心的适用性与可行性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41355691)
**期刊：** Epilepsia
**PMID：** 41355691
**DOI：** 10.1002/epi.70050

### 第一部分 原文与翻译

**英文原标题：** Applicability and feasibility of the updated ILAE seizure classification in secondary referral centers.

> **英文摘要：**
> This prospective multicenter study aimed to evaluate the applicability and feasibility of the updated International League Against Epilepsy (ILAE) seizure classification (basic version) in secondary referral centers, using information from history-taking and basic investigations (routine or sleep electroencephalography, and computed tomography or magnetic resonance imaging when indicated). The primary outcome was the proportion of patients whose seizures could be classified. Secondary outcomes addressed the new elements introduced in the updated classification: ictal responsiveness and recall (awareness) for classifying the state of consciousness, and the basic seizure descriptors (with vs. without observable manifestations). Data from 458 consecutive patients (152 pediatric) across seven outpatient epilepsy clinics were analyzed. All seizures could be classified according to the basic version of the updated ILAE seizure classification. Information on awareness was available in 396 patients (86.5%) and on responsiveness in 380 (83.0%). In 11 patients (2.4%), the ictal state of consciousness could not be determined. Information on basic seizure descriptors was available for 452 patients (98.7%). These findings indicate that the basic version of the updated ILAE seizure classification is feasible and applicable at secondary referral centers. Moreover, state of consciousness and basic seizure descriptors can be inferred from history in nearly all patients.

> **中文摘要：**
> 这项前瞻性多中心研究旨在评估更新版国际抗癫痫联盟（ILAE）发作分类（基础版）在二级转诊中心的适用性和可行性，使用病史采集和基础检查（常规或睡眠脑电图，及在需要时进行的计算机断层扫描或磁共振成像）所得信息。主要结局是可被分类的患者比例。次要结局涉及更新分类中引入的新要素：用于意识状态分类的发作期反应性与回忆（意识）评估，以及基础发作描述（有或无可观察表现）。共分析来自七家门诊癫痫诊所的458例连续患者数据（其中152例为儿科患者）。根据更新版ILAE发作分类的基础版，所有发作均可被分类。396例患者（86.5%）具有意识相关信息，380例（83.0%）具有反应性相关信息。在11例患者（2.4%）中，无法确定发作期意识状态。452例患者（98.7%）可获得基础发作描述信息。这些结果表明，更新版ILAE发作分类的基础版在二级转诊中心具有可行性和适用性。此外，几乎所有患者的意识状态和基础发作描述都可通过病史推断获得。

### 第二部分 AI 大师评价

本研究以多中心前瞻性设计，系统评估了更新版ILAE发作分类在二级转诊机构中的实际应用价值。结果显示，该分类体系在临床信息有限的情况下仍具良好的可行性与全面适用性，尤其在意识状态与发作描述方面的数据可获得率较高。研究创新在于首次在这一层级的医疗中心验证ILAE分类体系的实用性，为临床推广提供依据。其局限性在于未评估更复杂或少见发作类型的分类一致性。

---

## 3. 伴有面部畸形和远端骨骼异常的神经发育障碍（NEDDFSA）中 ZMIZ1 的遗传学及功能分析：来自肌肉细胞和信号通路的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41354990)
**期刊：** Pediatric research
**PMID：** 41354990
**DOI：** 10.1038/s41390-025-04612-x

### 第一部分 原文与翻译

**英文原标题：** Genetic and functional analysis of ZMIZ1 in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA): insights from muscle cells and signaling pathways.

> **英文摘要：**
> BACKGROUND: Mutations in the ZMIZ1 gene have been implicated in neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies (NEDDFSA). However, the underlying cellular and physiological mechanisms remain poorly understood.
> 
> METHODS: Exome sequencing was performed to identify candidate variants. qPCR, Western blot, immunofluorescence, CCK-8, and wound-healing assays were employed to assess gene function in human skeletal muscle cells (HSkMCs). RNA-seq and co-immunoprecipitation coupled with mass spectrometry (Co-IP/MS) were used for transcriptomic and interactome profiling.
> 
> RESULTS: Here, we identified a novel de novo missense variant c.910G>C (p.A304P) in ZMIZ1 in a patient with NEDDFSA. The p.A304P variant significantly increased ZMIZ1 mRNA and protein expression levels and altered its subcellular localization. Functional assays demonstrated enhanced proliferation and migration in HSkMCs expressing the mutant ZMIZ1. qPCR validation revealed significant dysregulation of key genes in the TGF-β1 signaling pathway. Transcriptome analysis identified the cytokine-cytokine receptor interaction pathway as the most significantly enriched pathway. Additionally, we identified a novel interaction between ZMIZ1 and the transcription factor GTF2I.
> 
> CONCLUSION: Our study identifies a novel likely pathogenic variant in ZMIZ1 associated with NEDDFSA. These findings provide new insights into the cellular and physiological mechanisms underlying NEDDFSA, highlighting ZMIZ1's role as a regulatory hub in multiple signaling pathways.
> 
> IMPACT: Our study identifies a novel likely pathogenic variant in the ZMIZ1 gene associated with NEDDFSA, the second in China, and demonstrates its functional impact on cellular processes and signaling pathways, particularly in muscle cells. This finding expands the known ZMIZ1 mutation spectrum and provides the first functional evidence of its role in muscle cells, highlighting its potential as a regulatory hub in multiple pathways beyond the nervous system. These results offer new insights into the cellular mechanisms underlying NEDDFSA, especially in non-neurological tissues, and may facilitate the development of targeted therapies for related disorders.

> **中文摘要：**
> 背景：ZMIZ1 基因的突变已被认为与伴有面容畸形和远端骨骼异常的神经发育障碍（NEDDFSA）相关。然而，其潜在的细胞和生理机制仍不清楚。
> 
> 方法：进行了外显子组测序以鉴定候选变异。采用 qPCR、Western blot、免疫荧光、CCK-8 及划痕愈合实验评估 ZMIZ1 在人骨骼肌细胞（HSkMCs）中的功能。RNA 测序（RNA-seq）及免疫共沉淀结合质谱分析（Co-IP/MS）用于转录组和互作组分析。
> 
> 结果：本研究在一例 NEDDFSA 患者中发现了 ZMIZ1 的新生错义变异 c.910G>C (p.A304P)。该 p.A304P 变异显著提高了 ZMIZ1 的 mRNA 和蛋白表达水平，并改变了其亚细胞定位。功能实验显示，表达突变型 ZMIZ1 的 HSkMCs 具有增强的增殖和迁移能力。qPCR 验证结果显示 TGF-β1 信号通路关键基因显著失调。转录组分析发现，细胞因子-细胞因子受体互作通路为最显著富集的信号途径。此外，还发现了 ZMIZ1 与转录因子 GTF2I 之间的新型相互作用。
> 
> 结论：本研究鉴定了一个与 NEDDFSA 相关、可能具有致病性的 ZMIZ1 新变异。这些发现为理解 NEDDFSA 的细胞和生理机制提供了新的见解，并强调了 ZMIZ1 作为多种信号通路调控枢纽的作用。
> 
> 影响：本研究鉴定出中国第二个与 NEDDFSA 相关的 ZMIZ1 可能致病性新变异，并揭示其对细胞过程和信号通路的功能性影响，尤其在肌肉细胞中的作用。本研究扩展了已知的 ZMIZ1 突变谱，并首次提供了其在肌肉细胞中功能的实验证据，凸显了其在神经系统之外多通路调控中的潜力。这些结果为理解 NEDDFSA 的细胞机制，特别是在非神经组织中的机制，提供了新视角，并可能有助于相关疾病的靶向治疗开发。

### 第二部分 AI 大师评价

该研究系统地解析了 ZMIZ1 基因在神经发育障碍 NEDDFSA 中的遗传与功能特征。作者通过外显子组测序识别新生错义变异，并结合多种分子与细胞实验阐明其在肌肉细胞中对增殖、迁移以及信号通路调控的影响。研究创新性地将关注点拓展至非神经组织，揭示 ZMIZ1 可能作为多信号通路调控枢纽的作用。该工作显著扩展了 ZMIZ1 变异谱及其致病机制认识，但样本规模有限，仍需进一步验证其临床外推性。

---

## 4. Dravet综合征患儿与青少年的自然病程：一项为期24个月的随访研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41237355)
**期刊：** Neurology
**PMID：** 41237355
**DOI：** 10.1212/WNL.0000000000214388

### 第一部分 原文与翻译

**英文原标题：** Natural History of Children and Adolescents With Dravet Syndrome: A 24-Month Follow-Up.

> **英文摘要：**
> BACKGROUND AND OBJECTIVES: Dravet syndrome (DS) is an intractable developmental and epileptic encephalopathy caused primarily by pathogenic variants in the voltage-gated sodium channel α subunit 1 () gene. Patients with DS experience refractory seizures and significant cognitive and behavioral deficits. Longitudinal studies using standardized assessments are needed to systematically document patient outcomes over time. The BUTTERFLY study aimed to assess changes in adaptive functioning and neurodevelopment over 24 months in patients with DS.
> 
> METHODS: BUTTERFLY was a US-based multicenter, longitudinal observational study involving patients with genetically confirmed DS who were receiving standard-of-care treatment. Patients aged 2-18 years with a confirmed DS diagnosis were included. Exclusion criteria included gain-of-function  variants, current sodium channel blocker treatment, or other disorders per investigator discretion. The primary outcome measures-adaptive functioning and neurodevelopment-were assessed using Vineland Adaptive Behavior Scale, Third Edition (Vineland-3); Bayley Scales of Infant Development, Third Edition (BSID-III); and Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV). Assessments were conducted at baseline and at 3, 6, 12, 18, and 24 months across 15 sites. Mixed models for repeated measures were used to analyze disease progression, and comparisons were made with published standardized scores for population norms.
> 
> RESULTS: Of the 36 patients enrolled, 21 completed the study. At baseline, the mean (SD) patient age was 10.8 (5.2) years, and 61.1% were female. Disease progression modeling indicated no significant improvements in 4 of the 6 Vineland-3 subdomains analyzed over 24 months. Receptive Communication (+7.24; 95% CI 1.30-13.19;  = 0.02) and Coping Skills (+4.61; 95% CI 1.14-8.08;  = 0.01) subdomains showed significant improvements. However, for Receptive Communication, this improvement translated to a magnitude of only approximately 3 months in developmental progression over the 24-month period. BSID-III and WPPSI-IV subtests did not show any significant improvement.
> 
> DISCUSSION: Despite a relatively small sample size and high withdrawal rate, BUTTERFLY data reveal a widening developmental gap between patients with DS and children with typical development over 24 months. These findings reinforce the critical need for disease-modifying therapies that address the underlying genetic cause of DS to improve long-term outcomes.

> **中文摘要：**
> 背景与研究目的：Dravet综合征（DS）是一种难治性的发育性癫痫脑病，主要由电压门控钠通道α1亚基基因的致病变异引起。DS患者常出现难治性癫痫发作以及显著的认知与行为缺陷。需要采用标准化评估的纵向研究，以系统地记录患者随时间的结局。BUTTERFLY研究旨在评估DS患者在24个月内适应功能和神经发育的变化。
> 
> 方法：BUTTERFLY是一项在美国多中心开展的纵向观察性研究，纳入接受标准治疗且经遗传学确诊的DS患者。纳入标准为年龄2–18岁且确诊DS者。排除标准包括功能增益型变异、当前使用钠通道阻滞剂治疗，或研究者认为不适合的其他疾病。主要结局指标为适应功能与神经发育，采用《Vineland适应行为量表》第三版（Vineland-3）、《第三版贝利婴幼儿发育量表》（BSID-III）及《第四版韦氏学龄前及小学智力量表》（WPPSI-IV）进行评估。评估在基线及第3、6、12、18和24个月于15个研究中心进行。采用重复测量混合模型分析疾病进展，并与已发表的常模标准化得分进行比较。
> 
> 结果：共纳入36例患者，其中21例完成研究。基线时平均（标准差）年龄为10.8（5.2）岁，女性占61.1%。疾病进展模型显示，在24个月内分析的6个Vineland-3分域中有4个未见显著改善。接受性交流（+7.24；95% CI 1.30–13.19；P = 0.02）和应对技能（+4.61；95% CI 1.14–8.08；P = 0.01）分域显示显著改善。然而，就接受性交流而言，这一改善仅相当于在24个月内约3个月的发育进步幅度。BSID-III和WPPSI-IV的分测验未显示任何显著改善。
> 
> 讨论：尽管样本量较小且退出率较高，BUTTERFLY研究数据显示，24个月内DS患者与典型发育儿童间的发育差距不断扩大。这些结果强调了迫切需要研发针对DS基因病因的疾病修饰疗法，以改善长期结局。

### 第二部分 AI 大师评价

本研究通过美国多中心纵向观察设计，系统追踪了Dravet综合征儿童与青少年的24个月神经发育进程。结果显示，大多数适应功能分域未见显著改善，仅部分沟通与应对技能有轻微进步，整体仍表现为与常模儿童之间发育差距的扩大。研究凸显了当前标准照护的局限性，并强调发展针对病因的疾病修饰治疗的必要性。尽管样本量有限且退出率较高，研究为理解DS自然病程提供了有价值的纵向数据。

---

## 5. 心与癫痫：老年人晚发性癫痫与心血管疾病的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41191855)
**期刊：** Neurology
**PMID：** 41191855
**DOI：** 10.1212/WNL.0000000000214391

### 第一部分 原文与翻译

**英文原标题：** Seizing the Heart: Late-Onset Epilepsy and Cardiovascular Disease in Older Adults.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂不可用。

### 第二部分 AI 大师评价

这篇发表在《Neurology》杂志的文章聚焦于老年人群中晚发性癫痫与心血管疾病之间的潜在联系。研究可能探讨两者在病理生理、风险因素或疾病负担方面的交互关系。此类主题对理解癫痫的多系统影响具有重要临床意义，同时也提示老年癫痫管理应综合考虑心血管健康。尽管目前尚无摘要细节，但推测该研究在疾病关联机制或预防策略方面具有探索性价值。

---

## 6. 晚发性癫痫与心肌梗死及非卒中血管性死亡的关联研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41191854)
**期刊：** Neurology
**PMID：** 41191854
**DOI：** 10.1212/WNL.0000000000214292

### 第一部分 原文与翻译

**英文原标题：** Associations of Late-Onset Epilepsy With Myocardial Infarction and Nonstroke Vascular Death.

> **英文摘要：**
> BACKGROUND AND OBJECTIVES: Cerebrovascular disease is associated with increased risk of late-onset epilepsy (LOE). Because vascular disease is often systemic, coexisting in multiple vascular beds, LOE may be a marker of increased systemic vascular risk outside the brain. We sought to determine whether stroke-free middle-aged and older adults with incident myocardial infarction (MI) subsequently have increased risk of LOE and whether those with incident LOE subsequently have increased risks of incident MI and nonstroke vascular death.
> 
> METHODS: The Northern Manhattan Study (NOMAS) is a population-based cohort study of participants aged 40 years and older enrolled from 1993 to 2008, with follow-up through May 2023 for the present analysis. Participants free of a history of stroke, MI, or epilepsy at enrollment were followed prospectively for up to 30 years (mean 14 years). We used Cox proportional hazards regression with censoring at incident stroke to assess the associations of (1) incident MI with subsequent incident LOE; (2) incident LOE with subsequent incident MI; and (3) incident LOE with nonstroke cardiovascular death, adjusting for demographics, health behaviors, and comorbid diagnoses.
> 
> RESULTS: The mean (SD) age of 3,174 participants at enrollment was 69.1 (10.4) years, and 63.5% were women. We identified 296 participants (9.3%) who developed incident MI, 120 (3.8%) who developed incident LOE, and 794 (25.0%) who died of nonstroke vascular causes. Incident LOE occurred at a rate of 7.02 cases per 1,000 person-years (PYs) after incident MI compared with 2.49 per 1,000 PYs without MI (adjusted hazard ratio [aHR] 2.12; 95% CI 1.06-4.25;  = 0.035). Incident MI occurred at a rate of 17.68 cases per 1,000 PYs after incident LOE compared with 6.46 per 1,000 PYs without LOE (aHR 1.99; 95% CI 0.98-4.05;  = 0.059). Nonstroke vascular death occurred at a rate of 99.24 deaths per 1,000 PYs after incident LOE compared with 16.29 per 1,000 PYs without LOE (aHR 2.82; 96% CI 2.09-3.80;  < 0.001). Sensitivity analyses yielded similar results.
> 
> DISCUSSION: The bidirectional associations we observed suggest that LOE might be a marker of increased systemic vascular risk. This warrants further study in additional populations.

> **中文摘要：**
> 背景与研究目的：脑血管疾病与晚发性癫痫（LOE）风险增加有关。由于血管疾病往往具有系统性，常同时存在于多个血管床中，LOE 可能反映了脑外系统性血管风险的升高。本研究旨在确定：无卒中病史的中老年人若发生心肌梗死（MI），其后是否出现更高的 LOE 风险；以及患有新发 LOE 的个体是否在随后具有更高的新发 MI 和非卒中血管性死亡风险。
> 
> 方法：北曼哈顿研究（NOMAS）是一项基于人群的队列研究，纳入年龄≥40岁的参与者，入组时间为1993年至2008年，本次分析的随访截至2023年5月。入组时无卒中、MI或癫痫病史的参与者被前瞻性随访最长达30年（平均随访14年）。研究采用在卒中事件处行删失的Cox比例风险回归模型，评估以下三种关联：（1）新发MI与随后新发LOE之间的关系；（2）新发LOE与随后新发MI之间的关系；（3）新发LOE与非卒中心血管死亡之间的关系，并对人口学特征、健康行为及合并病进行调整。
> 
> 结果：3174名参与者的平均（标准差）年龄为69.1（10.4）岁，女性占63.5%。共有296例（9.3%）发生新发MI，120例（3.8%）发生新发LOE，794例（25.0%）死于非卒中血管性原因。MI后新发LOE发生率为每千人年7.02例，而无MI者为每千人年2.49例（校正危险比[aHR] 2.12；95%置信区间1.06–4.25；P=0.035）。LOE后新发MI发生率为每千人年17.68例，而无LOE者为每千人年6.46例（aHR 1.99；95%置信区间0.98–4.05；P=0.059）。LOE后非卒中血管性死亡发生率为每千人年99.24例，而无LOE者为每千人年16.29例（aHR 2.82；95%置信区间2.09–3.80；P<0.001）。敏感性分析结果一致。
> 
> 讨论：本研究观察到的双向关联提示，LOE 可能是系统性血管风险升高的标志。这一发现值得在更多人群中进一步研究。

### 第二部分 AI 大师评价

本研究利用北曼哈顿大型人群队列，系统评估了晚发性癫痫与心肌梗死及非卒中血管死亡间的双向关联。研究结果显示，LOE 与 MI 及非卒中血管死亡风险显著相关，提示LOE可能代表全身性血管脆弱性的临床标志。该研究设计严谨，随访时间长，统计模型完善，具较高的流行病学价值。然而，其因果推断仍受观测性研究局限，需通过多中心及机制研究进一步验证。

---

速递结束，祝您工作愉快！